Research programme: anticancer therapeutics - Plexxikon/GenentechAlternative Names: PLX 152; PLX 225; PLX 391; PLX 628; PLX 630; PLX 762
Latest Information Update: 25 Mar 2009
At a glance
- Originator Plexxikon
- Developer Genentech; Plexxikon
- Class Small molecules
- Mechanism of Action Protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 21 May 2003 Preclinical trials in Cancer in USA (unspecified route)